KBC Group NV Has $5.56 Million Stock Holdings in CRISPR Therapeutics AG $CRSP

KBC Group NV grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3,999.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 116,847 shares of the company’s stock after buying an additional 113,997 shares during the quarter. KBC Group NV’s holdings in CRISPR Therapeutics were worth $5,558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. GSK plc bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth $168,890,000. Orbis Allan Gray Ltd lifted its position in CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the period. State Street Corp grew its stake in CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after buying an additional 859,334 shares in the last quarter. ARK Investment Management LLC grew its stake in CRISPR Therapeutics by 7.5% during the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after buying an additional 735,084 shares in the last quarter. Finally, Norges Bank bought a new position in CRISPR Therapeutics in the 4th quarter valued at about $25,706,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $47.53 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The stock has a market cap of $4.58 billion, a PE ratio of -7.64 and a beta of 1.71. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The firm’s fifty day moving average price is $52.69 and its two-hundred day moving average price is $52.76.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. On average, equities analysts expect that CRISPR Therapeutics AG will post -4.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. UBS Group set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 12th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, July 8th. Wall Street Zen downgraded shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 5th. Sanford C. Bernstein upped their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares of the company’s stock, valued at $1,076,636.34. This represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.